EAU 2013 - Programme Book - YouMed

Monday, 18 March - EAU Programme
Abstract Session
09.15 - 10.45 Current and new treatments of OAB and LUTS
Silver Hall - Level N2
Poster Session 61
Chairs: M.J. Drake, Bristol (GB)
H. Hashim, Bristol (GB)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
736 The clustering of lower urinary tract syndrome. Is the overactive bladder a distinct clinical syndrome?
P.O. Pal, B.H. Maraj, M. Ghei, J. Malone-Lee (London, United Kingdom)
737 Developing a psychometrically validated urinary diary
E. Bright, N. Cotterill, M. Drake, P. Abrams (Bristol, United Kingdom)
* 738 Urinary retention following anticholinergics in patients with BPH, do comorbidities matter? A nationwide
population-based study
E.Y-H Huang, C-C. Lin, H-J. Chung, J-P. Lin, A.T. Lin, K-K. Chen (Taipei, Taiwan)
739 Cardiovascular (CV) assessments in short- and long-term Phase 3 mirabegron trials in patients with
overactive bladder (OAB)
S. Herschorn, P. Kowey, V. Nitti, I. Milsom, S.M. Auerbach, M.B. Blauwet, C. Dorrepaal, M. Weber, J.S. Borer,
W. Fitzsimmons, N. Martin (Toronto, Canada; Wynnewood, New York, Newport Beach, Northbrook, United
States of America; Gothenburg, Sweden; Leiderdorp, The Netherlands)
740 A randomised controlled trial of fesoterodine in subjects with overactive bladder and suboptimal response
to tolterodine extended release: Results from the AFTER study
L. Cardozo, S. Kaplan, S. Herschorn, L. Grenabo, M. Carlsson, D. Arumi, T.J. Crook, L. Whelan, F. Ntanios
(London, Walton Oaks, United Kingdom; New York, United States of America; Toronto, Canada; Gothenburg,
Sweden; Madrid, Spain)
741 Pivotal phase 3 study in overactive bladder (OAB) patients with urinary incontinence confirms
onabotulinumtoxinA 100U significantly improves all OAB symptoms and patients’ quality of life
C. Chapple, K-D. Sievert, S. MacDiarmid, V. Khullar, P. Radziszewski, C. Nardo, C. Thompson, J. Zhou,
C. Haag-Molkenteller (Sheffield, London, Marlow, United Kingdom; Tübingen, Germany; Greensboro, Irvine,
United States of America; Warsaw, Poland)
742 A prospective randomized comparative study of first-line tolterodine and doxazosin monotherapy for men
with predominant storage symptoms
C.H. Liao, H-C. Kuo (New Taipei City, Hualien, Taiwan)
743 Prevalence and management of overactive bladder patients in the French general population in 2012
P. Grise, G. Amarenco, A. Bellessort, F. Bruyère, E. Chartier-Kastler, B. Fatton, F. Haab, A. Serikoff (Rouen,
Paris, Levallois-Perret, Tours, Nimes, France)
744 OnabotulinumtoxinA 100U demonstrates similar treatment effect in overactive bladder patients with
urinary incontinence regardless of number of prior anticholinergics taken or reason for their inadequate
management of patients’ overactive bladder
C. Chapple, K-D. Sievert, S. Herschorn, C. Thompson, C. Nardo, J. Zhou, C. Haag-Molkenteller, V. Nitti
(Sheffield, Marlow, United Kingdom; Tübingen, Germany; Toronto, Canada; Irvine, New York, United States
of America)
EAU Milan 2013
245
Monday